2820 3 ABSTRACT Background Maturity-onset diabetes of the young (MODY) is a heterogeneous group of monogenic disorders of impaired glucose-stimulated insulin secretion (GSIS). Mechanisms include β-cell KATP channel dysfunction (e.g., KCNJ11 (MODY13) or ABCC8 (MODY12) mutations); however, no other β-cell channelopathies have been identified in MODY.
Conclusions
Our data identify a novel MODY-associated gene, KCNK16; with a gain-of-function mutation limiting Ca 2+ influx and GSIS. A gain-of-function common polymorphism in KCNK16 is associated with type 2 diabetes (T2DM); thus, our findings have therapeutic implications not only for KCNK16-associated MODY but also for T2DM.
INTRODUCTION
Maturity-onset diabetes of the young (MODY) is a rare monogenic cause of familial diabetes. To date, 13 MODY genes have been confirmed, all involved in pancreatic β-cell insulin secretion and all with autosomal dominant transmission 1 . 2-2.5% of pediatric diabetes cases carry pathogenic/likely pathogenic variants in MODY genes 2, 3 ; however, MODY is often undiagnosed, either because the diagnosis is not considered 4 or because genetic screening is limited. There are also cases with compelling clinical histories in whom, despite comprehensive screening of known MODY genes, a genetic diagnosis cannot be made 3 , suggesting as-yet-unidentified genetic cause(s).
β-cell glucose-stimulated insulin secretion (GSIS) is dependent on Ca 2+ influx, through voltage-dependent calcium channels (VDCC) 5, 6 . Reduced Ca 2+ influx decreases GSIS; thus mutations that disrupt β-cell Ca 2+ entry can cause MODY or the closely-related condition neonatal diabetes 7, 8 . For example, gain-of-function mutations in KATP channel subunits hyperpolarize the β-cell membrane potential, reducing VDCC activity, Ca 2+ influx and GSIS 7, 8 . Other β-cell K + channels, including two-pore domain K + channels (K2P), also affect VDCC activity 9 . Expression of KCNK16, which encodes TWIK-related alkaline pH-activated K2P (TALK-1) 10 , is the most abundant and β-cell-selective of all human K + channel transcripts 11, 12 ; and TALK-1 gain-offunction mutations would be predicted to cause diabetes similarly 9 .
Here we have used exome sequencing to identify the first family with MODY due to a mutation in KCNK16.
The Leu114Pro substitution in TALK-1 affects the K + selectivity filter, causing a profound increase in K + current, altering β-cell Ca 2+ flux, and decreasing GSIS in both human and mouse islet cells.
METHODS

Clinical Recruitment
A four-generation family with six affected family members with autosomal dominant diabetes was identified through a non-obese proband who presented aged 15 years ( Fig.1A) with elevated fasting plasma glucose (7.8mmol/L) and an abnormal oral glucose tolerance test (glucose 19.6mmol/L two hours after 75g glucose). Antibody testing (islet cell, islet antigen 2, and glutamic acid decarboxylase-65) was negative. Over two decades, the proband required minimal insulin to maintain HbA1c of 5.7-6.5%; and she did not experience ketosis or other diabetes-related complications. Sanger sequencing for mutations in GCK, HNF1A and HNF4A (the commonest MODY genes) was negative. Other family members manifest diabetes similarly (detailed in Supplementary Appendix: Extended Clinical Data). The study protocol was approved by the relevant human research ethics committee (approval HREC/12/QPAH/109). All living family members gave written informed consent.
Exome sequencing.
Exome sequencing, pipeline processing, quality control and variant curation was performed as previously described 13 (detailed in Supplementary Appendix: Methods). Exome data from the proband was analysed for good-quality likely damaging rare variants in known MODY genes 1 , using a conservative minor allele frequency (MAF) threshold of <0.001, based on: (a) prevalence of paediatric diabetes of 0.2% 14 ; and (b) prevalence of MODY mutations in 2% of a pediatric diabetes population 2 ; further, most MODY mutations are private. Exome sequence data from the pedigree was analysed for novel and rare (MAF<0.001) good quality variants, of potentially damaging consequence, affecting highly conserved bases with appropriate segregation (i.e., heterozygous in affected individuals, absent in unaffected individuals).
Plasmids and Transient Expression
Human TALK-1 wildtype (WT) and TALK-1 Leu114Pro constructs were created by site-directed mutagenesis and then cloned into a vector containing a P2A cleavage site followed by mCherry (Supplementary Appendix: Fig. S1 ). HEK293 cells, which have no endogenous TALK-1 expression, were transfected with 2µg DNA using Lipofectamine 3000 (Life Technologies). Transfection efficacy was assessed and quantified using mCherry Fluorescence. (Supplementary Appendix: Methods and Fig. S2 ).
Lentivirus Production
HEK293 cells were transfected with lentiviral-producing plasmids; the plasmids used included the packaging plasmid (pCMV-dR7.74psPAX2), envelope plasmid (pMD2.G), and an expression plasmid (detailed in Supplementary Appendix: Methods and Fig. S1 ). Lentiviral-containing supernatants were collected three days after transfection and used for transduction of primary beta--cells; after transduction, equal TALK-1 expression was confirmed by equivalent mCherry expression (detailed in Supplementary Appendix: Methods and Fig. S3 ).
Electrophysiological Recordings
TALK-1 channel currents were recorded in HEK293 cells using a whole-cell voltage-clamp technique with an Axopatch 200B amplifier and pCLAMP10 software (Molecular Devices), as previously described 9 ; singlechannel current recordings of TALK-1 were recorded with an cell-attached voltage-clamp technique also as previously described 15 (detailed in Supplementary Appendix: Methods and Fig. S4 ).
Islet and -Cell Isolation
Islets were isolated from mouse pancreata as previously described 9 . Human islets from non-diabetic adult donors were provided by isolation centers of the Integrated Islet Distribution Program (donor information, Supplementary Appendix: Table S1 ). Some islets were dispersed into cell clusters and then cultured for 12-18 hours 9 . Cells were maintained in RPMI 1640 with 15% FBS, 100IU/mL penicillin, and 100mg/mL streptomycin in a humidified incubator at 37°C with an atmosphere of 95% air and 5% CO2.
Calcium handling measurements
Islets were incubated for 25min in RPMI supplemented with Fura-2, AM (Molecular Probes), followed by incubation in Krebs-Ringer-HEPES buffer with 2mmol/L glucose for 20min 9 . For cytoplasmic Ca 2+ [Ca 2+ cyto]:
Ca 2+ imaging was performed as previously described 9 , switching from 2mM glucose to 20mM glucose. For endoplasmic reticulum (ER) Ca 2+ [Ca 2+ ER]: Islets were perfused in Krebs-Ringer-HEPES buffer without extracellular Ca 2+ and 100 M diazoxide and monitored for Ca 2+ ER release mediated through blockade of the sarco(endo)plasmic reticulum Ca 2+ -ATPase (SERCA) with 50 M cyclopiazonic acid (CPA, Alomone labs), as previously described 16 .
Insulin Secretion Measurements
Islets were transduced with lentiviruses containing a RIP promoter 17 upstream of either TALK-1 WT or TALK-1 Leu114Pro followed by a P2A cleavage site and NanoLuc-proinsulin (Supplementary Appendix: Fig.   S1 ) 18, 19 . Importantly, NanoLuc is co-secreted with insulin, enabling measurement of insulin secretion specifically from cells expressing either the TALK-1 WT or TALK-1 Leu114Pro construct 18 . Insulin secretion was measured as previously described 18 (detailed in the Supplementary Appendix: Methods).
Statistical Analyses
Functional data were analyzed using pCLAMP10 or Microsoft Excel and presented as mean ± SEM.
Statistical significance was determined using Student's t-test; a two-sided P-value ≤0.05 was considered statistically significant.
RESULTS
Exome sequencing in a family with MODY identifies a novel variant in KCNK16
Exome sequencing and analysis of known MODY genes in the proband identified a splice site mutation in ABCC8 (NM_000352 c.1332+4 delC); however, this variant was not predicted to affect splicing 20 and did not segregate appropriately in the pedigree.
Exome sequencing and analysis of the extended pedigree identified novel good-quality coding variants in two genes, KCNK16 and USP42, with appropriate segregation ( Fig. 1A and 1B ; coverage statistics for exome sequencing, Supplementary Appendix: Table S2 ; exome data filtering, Supplementary Appendix: Table S3 ). USP42 (Ubiquitin-specific peptidase 42) is involved in spermatogenesis 21 and is not expressed in the pancreas; and was considered an unlikely MODY candidate. However, KCNK16 (Potassium channel, subfamily K, member 16) encodes for TALK-1, with its established role in GSIS 9 . Further, the KCNK16containing locus is associated with T2DM 9,22,23 .
The KCNK16 variant (NM_001135105: c.341T>C) has not previously been reported in ExAC (http://exac.broadinstitute.org), 1000 Genomes (http://www.1000genomes.org), or dbSNP137 (http://www.ncbi.nlm.nih.gov/projects/SNP/) databases. It affects a highly conserved base (GERP score 5.65) with the resultant amino acid change (p.Leu114Pro) predicted to involve the pore domain one of TALK-1, immediately downstream of the GYG K + selectivity filter (Fig. 1C) . The GYG motif, and leucine 114 specifically, shows strong sequence homology with other K2P channels ( Fig. 1D ). As the crystal structure of TALK-1 is unpublished, TREK-2 was used to model the p.Leu114Pro mutation which demonstrated a conformational shift in both the GYG motif and pore domain (Fig. 1E) , strongly suggesting that TALK-1 Leu114Pro would significantly affect K + permeability.
TALK-1 Leu114Pro results in a gain-of-function
K + currents recorded using HEK293 cells transfected with either TALK-1 WT or TALK-1 Leu114Pro demonstrated that TALK-1 Leu114Pro caused a massive (312-fold) increase in whole-cell K + currents compared to TALK-1 WT (current at −40mV: TALK-1 Leu114Pro 774.16 ±218.75 pA vs. TALK-1 WT 2.48 ± 1.86 pA; Fig. 2A, 2B, Supplementary Appendix: Fig. S4 ). Individual TALK-1 channel activity showed a 3.6fold increase in current amplitude and a 2.9-fold increase in open probability at 100mV for TALK-1 Leu114Pro compared to TALK-1 WT (Fig. 2C, 2D , 2E, 2F) 15 . Thus, TALK-1 Leu114Pro is a gain-of-function mutation, predicted to cause hyperpolarization of the -cell membrane potential.
TALK-1 Leu114Pro reduces β−cell Ca 2+ influx and ER Ca 2+ stores
Ca 2+ handling was monitored in mouse β-cells following transduction of either TALK-1 WT or TALK-1 Leu114Pro. Glucose-stimulated (20mM) β-cell Ca 2+ influx was abolished by expression of TALK-1 Leu114Pro (Fig. 3A, 3C, and 3D ). TALK-1 has been previously shown to modulate Ca 2+ ER homeostasis by providing a countercurrent for Ca 2+ ER release 16 ; thus TALK-1 Leu114Pro control of Ca 2+ ER storage was also examined. Inhibition of SERCAs with CPA resulted in significantly less Ca 2+ ER release in β-cells expressing TALK-1 Leu114Pro compared to TALK-1 WT (62.6% decrease; Fig. 3E, 3F ), suggesting reduced Ca 2+ ER storage with TALK-1 Leu114Pro 16 . β-cells expressing TALK-1 Leu114Pro also showed elevated basal [Ca 2+ cyto] compared to β-cells expressing TALK-1 WT (28.8% increase in AUC; Fig. 3A, 3B ). Taken together, this suggests that under basal conditions, TALK-1 Leu114Pro enhances Ca 2+ ER leak, thereby increasing basal [Ca 2+ cyto]. Furthermore, the usual transient drop in β-cell [Ca 2+ cyto] following glucose stimulation of Ca 2+ ER uptake (termed phase-0) was amplified with TALK-1 Leu114Pro compared to TALK-1 WT 24 . These changes would be predicted to diminish GSIS.
DISCUSSION
We have identified the first family with MODY due to a mutation in KCNK16. The novel TALK-1 gain-offunction p.Leu114Pro mutation increases β-cell K + efflux resulting in membrane hyperpolarization, altering β-cell Ca 2+ handling and decreasing GSIS; and highlight the critical role of TALK-1 in −cell physiology. Unlike the only other MODY-associated K + channelopathy (i.e., KATP channel dysfunction), TALK-1 is unresponsive to sulfonylureas 9 . Thus our data suggest not only a novel therapeutic target for KCNK16-associated MODY but for other forms of diabetes also.
TALK-1 belongs to the K2P channel family characterized by constitutive K + flux, which serve critical roles setting the membrane potential of electrically excitable cells. The KCNK16 transcript encoding TALK-1 is the most abundant K + channel transcript in the human β-cell 11, 12 ; and KCNK16 shows the most isletselective expression of all ion channel transcripts 10, 25 . Similar to other K + channels, such as KATP 26 , TALK-1mediated hyperpolarization of mouse and human β-cell membrane potential limits VDCC activity, Ca 2+ entry and GSIS 9 . However, the KATP K + conductance is significantly greater than the small constitutive conductance of TALK-1 9,10,15,26 . Thus, TALK-1 mainly regulates the β-cell membrane potential following glucose stimulation, when KATP channels close: their activity limits islet Ca 2+ oscillation frequency and hence GSIS 9 . A gain-of-function TALK-1 mutation would be predicted to affect glucose tolerance adversely resulting in hyperglycemia, as demonstrated here.
The KCNK16-containing locus is strongly associated with T2DM, in multiple genome-wide association studies including populations with differing ethnicities 22, 23, [27] [28] [29] TALK-2 is also expressed in islet cells with high specificity, though lower than TALK-1 (islet expression specificity index for KCNK16=0.98 and for KCNK17=0.76) 30 . These data suggest that the association of this locus with T2DM is driven by more than one mechanism, with combined effects from overactive TALK-1 and overexpression of TALK-2, each of which potentially contributing to hyperpolarization of the β-cell membrane potential, reducing glucose-stimulated Ca 2+ influx and GSIS. That association is seen in T2DM with a common variant in the same gene in which we are now reporting a novel mutation causing MODY indicates that the encoded protein (i.e., TALK-1) is not functionally redundant; rather, that it is likely relevant to a high proportion of T2DM cases. These properties increase the potential of TALK-1 as a therapeutic target for T2DM.
Mutations in K2P channels causing dramatic changes in K + channel currents typically affect the pore domains of these channels [31] [32] [33] . For example, loss-of-function mutations in the first or second pore domains of KCNK3 (respectively, p.Gly97Arg and p.Gly203Asp) cause pulmonary hypertension 31 . Similarly, a loss-of-function mutation in the first pore domain of TASK-2 (p.Thr108Pro) causes Balkan Endemic Nephropathy 32 . A gain-of-function mutation (p.Gly88Arg) in the first pore domain of TALK-2, coded by KCNK17, causes a severe cardiac arrhythmia 33 ; and is the only previously identified disease-associated mutation in TALK channels.
Gain-of-function mutations in KATP significantly increase β-cell K + flux, resulting in neonatal diabetes and MODY 7, 8 . In contrast, TALK-1 p.Leu114Pro results in a more modest diabetes phenotype despite the 300-fold increase in whole-cell TALK-1 activity. This may because TALK-1 activation shows voltagedependence 9, 10 . Unlike KATP, which is active at all voltages, TALK-1 is an outward rectifying channel that shows increased activation during depolarization 9, 10 . Therefore, a gain-of-function in TALK-1 would be most active post-β-cell depolarization -limiting, but not abrogating, insulin secretion. The p.Leu114Pro mutation does increase TALK-1 current near the resting membrane potential ( Fig. 2A, and Supplementary   Appendix Fig. S4) ; however, this current is still less than the total β-cell KATP conductance under euglycemic conditions. These data concord with the proband's clinical phenotype, with dramatic glucose elevation after an oral glucose load but only a modest increase in fasting plasma glucose.
TALK-1 is expressed on both the β-cell plasma membrane and the ER membrane 16 . Ca 2+ ER release is balanced by negative charge on the luminal ER membrane; this charge is dissipated by ER TALK-1 K + influx leading to enhanced Ca 2+ ER release 16 . Thus overactive TALK-1 channels (e.g., TALK-1 Ala277Glu) increase Ca 2+ ER release, whereas TALK-1 ablation reduces Ca 2+ ER release 16 . Importantly, enhanced β-cell Ca 2+ ER release under hyperglycemic conditions results in ER-stress, contributing to β-cell dysfunction 34 . TALK-1
Leu114Pro may contribute to β-cell dysfunction via ER-stress, as observed in some MODY subtypes (e.g., INS mutations in MODY-10 35 ); however, this remains speculative. Additionally, although highly -cell specific, TALK-1 is also expressed in human pancreatic δ-cells where it negatively regulates somatostatin release 36 . TALK-1 KO mice show increased somatostatin secretion under low and high glucose conditions, due to enhanced Ca 2+ ER release 36 ; thus, a gain-of-function mutation in TALK-1 may reduce δ-cell somatostatin secretion. The glycemic effects of this would be complex given the inhibitory effect of somatostatin on both insulin and glucagon secretion 36 ; and require future investigation. Some MODY subtypes (e.g., ABCC8-, KCNJ11-, HNF1-and HNF4 MODY) are manageable through KATP inhibition 7,37,38 -i.e., sulfonylurea use. Although -cell membrane potential depolarization with sulfonylureas may allow greater VDCC activity, potentially increasing insulin secretion in affected individuals in this family, TALK-1 itself is not sensitive to sulfonylureas 9 . Further, and as detailed above, TALK-1 primarily modulates -cell membrane potential during active insulin secretion when KATP is closed (i.e., during hyperglycemic conditions) 9 . Thus, KATP inhibition may not completely normalize β-cell membrane potential or insulin secretion in individuals with TALK-1 gain-of-function MODY. This raises the possibility of TALK-1 inhibition as a druggable target. Genetic evidence whether from rare (e.g., MODY) or common (e.g., T2DM 22, 23, [27] [28] [29] ) human disease is a strong predictor of future successful drug development 39 . Thus our data have important therapeutic implications not only for TALK-1 MODY but also for the far more common form of diabetes T2DM.
In conclusion, we have identified a novel mutation in KCNK16 causing a gain-of-function in TALK-1, reducing glucose-stimulated Ca 2+ influx, Ca 2+ ER storage, and GSIS; and resulting in MODY. TALK-1 is the first ion channel linked to MODY after KATP; and is expressed more selectively in islet cells compared to KATP.
The KCNK16 locus is associated with T2DM risk in the general population. Our data suggest TALK-1 as an efficacious and islet-selective therapeutic target for both KCNK16-associated MODY and T2DM. 
